9Kristialasen MM, Leandro C, Ordway D, et al. Phenothia zincs al- ter resistance of methicillin resistant strains of Staphylococcus au- reus(MRSA) to oxacillininvitro[J]. Int J Anti mierob Agents, 2003,22 : 250.
10CDC. Staphylococcus aureus resistant to van comycin-United States, 2002[J].Morb Mortal Wkly Rep, 2002,51 (26) :565.
5Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomyein minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis, 2007, 44:1208-1215.
7Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomyein. Lancet, 1997, 350: 1670-1673.
8Cartolano GL, Cheron M, Benabid D, et al. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect, 2004, 10:448-451.
9Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin- intermediate Staphylococcus aureus. Clin Infect Dis, 2004, 38: 448-451.
10Fitzgibbon MM, Rossney AS, O' Connell B. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus. J Clin Microbiol, 2007, 45:3263-3269.
